Jazz Pharmaceuticals (JAZZ) Stock Forecast & Price Target

Jazz Pharmaceuticals is viewed positively because its diversified commercial base is broadening beyond Xyrem, with Xywav, Epidiolex, Zepzelca, Rylaze, Vyxeos, and Modeyso supporting revenue growth while reducing reliance on any single asset. The company’s momentum is reinforced by a strong Q1 revenue beat at $1.069B versus $983.2MM consensus and reiterated FY26 revenue guidance of $4.25-4.5B, while oncology upside is expanding with Ziihera’s 1L HER2+ GEA approval and management’s raised $3-5B peak sales view. Further, persistent patient adds in Xywav, 60% Y/Y growth in Zepzelca, and early uptake for Epidiolex and Modeyso suggest durable execution and meaningful pipeline optionality across neuroscience and oncology.

Jazz Pharmaceuticals is exposed to multiple fundamental headwinds, led by heavy dependence on the Xyrem franchise, which is the company’s major source of cash flow and could erode if generics gain traction despite patent defenses. The outlook is also pressured by regulatory and clinical uncertainty, including whether Phase 3 Zepzelca studies can show benefit in first line SCLC and whether early pipeline assets like JZP150 and JZP385 produce negative readouts. Commercially, slower-than-expected growth in Rylaze and Epidiolex, plus generic Xyrem, once-nightly Lumryz, and potential Epidiolex competition as early as after ODE expiration in 2027, create a difficult path for durable growth and liquidity.